<DOC>
	<DOC>NCT01876368</DOC>
	<brief_summary>This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan</brief_summary>
	<brief_title>Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>patients with mild to moderate hypertension, untreated or currently taking antihypertensive therapy treated patients (using antihypertensive drugs within 4 weeks prior to first visit) must have an office msSBP ≥ 145 mmHg and &lt; 180 mmHg after washout epoch and after 4 weeks runin epoch untreated patients (either newly diagnosed or those patients with a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to first visit) must have an offcie msSBP ≥ 150 mmHg and &lt; 180 mmHg at screening and 1 week after screening and must have an office msSBP ≥ 145 mmHg and &lt; 180 mmHg after 4 weeks runin epoch patients must successfully complete ABPM and pass technical requirements to be qualified for randomization Malignant or severe hypertension (grade 3 of WHO classification; msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg) History of angioedema, drugrelated or otherwise History or evidence of a secondary form of hypertension, including but not limited to any of the following: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease (PKD), druginduced hypertension Patients who previously entered a LCZ696 study and had been randomized or enrolled to receive active drug treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>hypertension,</keyword>
	<keyword>LCZ696,</keyword>
	<keyword>olmesartan</keyword>
</DOC>